MMP9 and cervical cancer: Also, EGCG (10 μM, 25 μM, 50 μM, 100 μM) was found to block the activity of MMP-2 and MMP-9 in pediatric human sarcomata (osteosarcoma U2 OS and rhabdomyosarcoma RD) [50], adult human sarcomata (chondrosarcoma SW-1353, fibrosarcoma HT-1080, liposarcoma SW-872, synovial sarcoma SW-982) [51], the human cervical cancer lines HeLa and DoTc2-4510, the human ovarian cancer line SK-OV-3 [52], and human renal cell carcinoma 786-0 (EGCG in concentrations 10 μM, 50 μM, 100 μM, 200 μM) [53].